To the average consumer, this may be a bit confusing here, but the purchase of this company will add to the existing suite of software from Oracle to help provide the pharmaceutical business a better look at their business models and most of all drug safety. Oracle was in the news this week providing it’s first every dividend, so this goes to show the business of collecting data in data base programs is not missing any steps and is alive and well, the information needs to be stored somewhere.
The Relsys system is probably best known for it’s starship product line, Argus Safely web which contains a multiple number of modules to build upon for designing a program to report on the desired results and it is compatible with both Oracle and Microsoft SQL server at present. One thing for sure we don’t seem to be short on the availability of analytical software today with Life Sciences, it’s just more of the where’s, who’s and how’s to configure that still represent a challenge when it comes to decision time. BD
Relsys will continue to operate independently until the deal closes, which is expected to take place by this summer.
Oracle already has a strong presence in the healthcare space -- the acquisition of Relsys only deepens the bench. Last year, the company formed a new global business unit for the health sciences industry, combining Oracle Clinical, Oracle Remote Data Capture, Oracle Thesaurus Management System, Oracle Adverse Event Reporting System, Oracle Life Sciences Data Hub and Oracle's Siebel Clinical Trial Management System.
Indeed, the health sciences space is going to be a major focus of investment for software vendors, if it isn't already, Paul Greenberg, author of CRM at the Speed of Light, told CRM Buyer.